A Phase 1 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With the LentiGlobin BB305 Lentiviral Vector in Subjects With Severe Sickle Cell Disease

Trial Profile

A Phase 1 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With the LentiGlobin BB305 Lentiviral Vector in Subjects With Severe Sickle Cell Disease

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs BB305 beta-globin gene therapy bluebird bio (Primary)
  • Indications Sickle cell anaemia
  • Focus Adverse reactions
  • Sponsors bluebird bio
  • Most Recent Events

    • 03 Feb 2017 According to a bluebird bio media release, the first patient has been treated under the amended study protocol in this trial.
    • 06 Dec 2016 Interim results (n=7 data cut off: Jul 2016) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 05 Dec 2016 Interim results from this trial presented at the American Society of Hematology (ASH) Annual Meeting, according to a bluebird bio media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top